+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are conducting an international, multicenter, randomized, controlled, open-label Phase III trial to evaluate the effectiveness and safety of libevitug in people with chronic Hepatitis Delta Virus HDV infection. The study focuses on participants aged 12 to 70 years who have a history of chronic HDV infection and specific liver enzyme levels. Participants will be assigned to one of three groups one group receiving libevitug at 20 mgkg every two weeks through intravenous infusion for 96 weeks another group receiving a lower dose of 10 mgkg on the same schedule and a control group observed for 48 weeks before then receiving the 20 mgkg libevitug dosage for the following 48 weeks. This setup allows comparison of different dosing and delayed treatment effects. Throughout the study, participants will undergo regular evaluations including liver function tests, viral load measurements, and liver stiffness assessments. The primary outcome is the proportion of participants achieving a significant reduction in HDV RNA and normalization of liver enzymes at week 48. Additional outcomes will be monitored up to week 120, including safety monitoring for adverse events. The total participation may last up to about two and a half years, with careful follow-up to assess long-term effects.

Age: 12Years - 70YearsAll GendersPhase 3
7 locations
S

Actively Recruiting

Researchers are conducting a multicenter, prospective observational study to investigate how often patients with Helicobacter pylori infection experience dyspeptic symptoms, such as indigestion. The study also aims to follow these patients after they undergo treatment to eradicate H. pylori to see how their dyspeptic symptoms improve over time. This research intends to guide better diagnosis and treatment strategies for patients with H. pylori infection and related digestive discomfort. Participants diagnosed with H. pylori infection confirmed by breath tests or gastroscopy will complete an epidemiological questionnaire and a Functional Dyspepsia Symptom Diary FDSD to record their symptoms. Patients who have dyspepsia and successfully clear the infection will be followed up at 2 months and again at 6 months to assess if their symptoms have improved. The study does not involve any experimental drugs or treatments but focuses on observation and symptom tracking. During the study, patients will provide basic health information and record their digestive symptoms in the diary. Researchers will track the occurrence of dyspepsia at the start and monitor symptom relief after treatment. The follow-up periods at 2 and 6 months after eradication therapy will help measure symptom changes. Participants may be involved for several months, contributing to a better understanding of the natural history of H. pylori-related dyspepsia and treatment outcomes.

Age: 18Years - 80YearsAll Genders
26 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of human umbilical cord-derived mesenchymal stem cells MSCs therapy for patients with decompensated cirrhosis, a serious liver condition with a high death rate. Liver transplantation remains the most effective treatment, but challenges like limited donor availability, high costs, and rejection restrict its use. Given these issues, this study aims to explore MSCs as a potential alternative therapy through a phase 2, multicenter, randomized, double-blind, placebo-controlled trial. Participants will be randomly assigned to receive either three intravenous doses of MSCs or a placebo at days 1, 8, and 15, alongside standard care. The trial will include 140 patients with decompensated cirrhosis, split evenly between the MSC treatment group and the placebo group. The study treatments are given through IV transfusions, and the trial will be conducted at multiple centers to assess both safety and treatment effects. During the trial, patients will undergo regular assessments including laboratory tests, clinical evaluations, and quality-of-life questionnaires over a period of up to 24 months. The main outcome measured is the change in the Model for End-Stage Liver Disease MELD score from baseline to day 28. Secondary outcomes include longer-term changes in MELD scores, incidence of complications, liver transplant-free survival, liver function tests, and monitoring of treatment-emergent adverse events. This comprehensive monitoring will help determine the potential benefits and risks of MSC therapy for this condition.

Age: 18Years - 75YearsAll GendersPhase 2
7 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting the IDEAL study, a large, multicenter, prospective, double-blind randomized controlled trial, to evaluate the impact of an artificial intelligence AI model on diagnosing intracranial aneurysms using head CT angiography CTA. The study aims to compare the diagnostic sensitivity and specificity of this AI-assisted approach against a sham AI method, while also assessing patient prognosis and various clinical outcomes. Over 6450 patients scheduled for head CTA will be enrolled across 21 hospitals in China. Participants will be randomly assigned to one of two groups the True-AI group, where radiologists use a deep-learning AI model with high sensitivity to assist in diagnosing intracranial aneurysms, and the Sham-AI group, where radiologists use a similar AI model with very low sensitivity but comparable specificity. Both groups will undergo their usual head CTA scans and diagnoses. The study includes a 12-month follow-up to monitor repeat imaging, clinical follow-up, treatment, and patient outcomes. During the study, patients will have their head CTA images interpreted with either the True-AI or Sham-AI assistance, without knowledge of group assignment by patients or radiologists. Researchers will assess diagnostic accuracy, detection rates of intracranial lesions, workload of CTA interpretation, resource use, hospitalization rates, quality of life measures, functional outcomes, and safety indicators at 3, 6, and 12 months. The primary outcomes focus on diagnostic sensitivity and specificity at 6 months, with secondary outcomes covering broader clinical and patient-centered measures over the follow-up period.

Age: 18Years +All GendersPhase Not Applicable
21 locations
E

Actively Recruiting

Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.

Age: 18Years +FEMALEPhase Not Applicable
110 locations
D

Actively Recruiting

Researchers are investigating the use of confocal technology, also known as optical biopsy, combined with double-balloon enteroscopy to improve real-time cellular-level examination of the small bowel. This study aims to establish a diagnostic framework for small bowel tumors and non-neoplastic lesions, as confocal endoscopy is currently used mainly for upper and lower gastrointestinal tract diseases. The project is focused on developing a quality assessment system for confocal enteroscopy procedures to enhance early diagnosis and staging of small bowel diseases such as inflammatory bowel disease and hereditary neoplastic syndromes. This project will create a multi-center cohort with 200 confocal small-bowel endoscopy cases and 400 gastrointestinal control cases divided equally into exploratory and validation arms. Patients with suspected small-bowel diseases who require endoscopy will be included. During single- or double-balloon enteroscopy, suspected areas and adjacent normal mucosa will be examined with confocal laser endomicroscopy CLE, and conventional enteroscopic findings will be recorded. CLE will assess various mucosal and inflammatory activity scores, supported by AI image-recognition systems. The exploratory arm will identify diagnostic parameters to build a new confocal enteroscopy model for small-bowel inflammatory bowel disease, which will then be tested in the validation arm. Quality-control indicators covering pre-, intra-, and post-procedure phases will also be developed and validated. Participants will undergo confocal small-bowel endoscopy with data collection on procedural success, diagnostic accuracy, complication rates, and image quality. The study will assess factors impacting quality control throughout the workflow, including preparation, procedure timing, scope handling, specimen management, and recovery. Regular audits will ensure continuous improvement. The primary outcome is procedural success rate within 14 days, with secondary outcomes including diagnostic accuracy and complication rates. The study will last until June 2028, involving adult participants aged 18 to 70 years.

Age: 18Years - 70YearsAll Genders
8 locations
E

Actively Recruiting

Researchers are evaluating the use of manual thrombus aspiration during primary percutaneous coronary intervention PCI in patients who have suffered a ST-segment Elevation Myocardial Infarction STEMI and have a high thrombus burden, defined as TIMI thrombus grade 3 or higher. This study aims to determine whether thrombus aspiration can reduce major cardiovascular events such as cardiovascular death, recurrent heart attacks, stent thrombosis, target vessel revascularization within 180 days, or stroke within 30 days after the procedure. Participants are randomly assigned in equal numbers to one of two groups one group receives upfront manual thrombus aspiration followed by PCI, while the other group undergoes PCI without thrombus aspiration. The procedures are performed within 12 hours of symptom onset. This open-label, multicenter trial compares the outcomes of these two approaches to better understand the potential benefits and risks of thrombus aspiration in this patient population. During the study, participants will be closely monitored for major adverse cardiovascular events up to 180 days after treatment, with additional assessments for stroke within 30 days and composite cardiocerebrovascular events up to one year. Researchers will collect clinical data to evaluate the effectiveness of the treatments. The total duration of participation includes these follow-up periods, ensuring thorough observation of safety and outcomes after the initial intervention.

Age: 18Years +All GendersPhase Not Applicable
50 locations